TherapeuticsMD, Inc. (TXMD) Return on equity 2016–2025
TherapeuticsMD, Inc. (TXMD) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-2.1%FY2025 · since FY2016: -70.5% → -2.1%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -2.1% | +5.9 pp |
| FY2024 | -8.0% | +27.1 pp |
| FY2023 | -35.1% | -353.8 pp |
| FY2022 | 318.7% | — |
| FY2019 | -1914.4% | -1778.4 pp |
| FY2018 | -136.0% | -76.8 pp |
| FY2017 | -59.2% | +11.3 pp |
| FY2016 | -70.5% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More TXMD financial trends
TXMD RevenueTXMD Net incomeTXMD Net marginTXMD Gross profitTXMD Gross marginTXMD Operating incomeTXMD Operating marginTXMD Operating cash flowTXMD Free cash flowTXMD Capital expendituresTXMD Stock buybacksTXMD Dividends paidTXMD Total assetsTXMD Total liabilitiesTXMD Shareholders’ equityTXMD overview →